Adversarial Injection · Polatuzumab Vedotin-piiq (Polivy; DCDS4501A; CAS 1313219-80-5; MW ~149 kDa [ADC]; humanized anti-CD79b IgG1 [clone 2F2-derived] conjugated to MMAE [monomethyl auristatin E; MW 717.9 g/mol; microtubule depolymerizing agent; antimitotic; vinca-binding β-tubulin site] via MC-VC-PABC [maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate; cathepsin B-cleavable] linker; DAR ~3.5; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST CD79B [IGβ; B-CELL RECEPTOR SIGNAL TRANSDUCER; CD79B GENE; CHROMOSOME 17q23.3; 229-AMINO-ACID TYPE I TRANSMEMBRANE; EXTRACELLULAR Ig-LIKE DOMAIN; INTRACELLULAR ITAM [IMMUNORECEPTOR TYROSINE-BASED ACTIVATION MOTIF]; CYTOPLASMIC Y196/Y231 PHOSPHORYLATION BY LYN/FYN → SYK RECRUITMENT → SYK → BTK → PLCγ2 → NF-κB/MAPK/PI3K; REQUIRED FOR BCR SURFACE EXPRESSION [PAIRS WITH CD79a/IGα → BCR HETERODIMER]; EXPRESSED ON MATURE B CELLS + DLBCL + FL + MZL + MCL; NOT T CELLS OR MYELOID] DIRECTED ADC WITH VEDOTIN (MMAE) WARHEAD EVER FDA APPROVED; POLARIX PFS HR 0.73; ROCHE/GENENTECH BLA 761121 JUNE 10 2019) · Attack #721

Polatuzumab Vedotin-piiq (ADC; CD79b-Targeted MMAE; Polivy; DCDS4501A; CAS 1313219-80-5; MW ~149 kDa; Roche/Genentech Inc. [South San Francisco CA US BLA 761121 holder; Polivy US commercial]; MECHANISM: FIRST CD79b [IGβ; B-CELL RECEPTOR SIGNAL TRANSDUCER; CHROMOSOME 17q23.3; 229-AA TYPE I TRANSMEMBRANE GLYCOPROTEIN; EXTRACELLULAR Ig-LIKE (V-SET) DOMAIN [BINDS ANTI-CD79b ANTIBODY EPITOPE]; TRANSMEMBRANE DOMAIN; CYTOPLASMIC ITAM DOMAIN [Y196xxL/Y231xxL DUAL TYROSINE MOTIF; LYN/FYN-MEDIATED PHOSPHORYLATION → SYK p-ITAM RECRUITMENT → ZAP70-LIKE KINASE → BTK/PLCγ2/PKCβ → NF-κB, PI3K, MAPK → B-CELL PROLIFERATION/SURVIVAL]; CD79B PAIRS WITH CD79a/IGα → CD79a-CD79b HETERODIMER REQUIRED FOR BCR (IgM/IgD/IgG/IgA/IgE) SURFACE EXPRESSION AND SIGNAL TRANSDUCTION; CD79B EXPRESSED: MATURE B CELLS (PRE-B → MATURE B, NOT PLASMA CELLS); DLBCL (>95%); FL (>90%); MZL/MCL/CLL; NOT T/NK/MYELOID → ADC SELECTIVITY; CD79B MUTATION: HD-DLBCL MYD88 L265P + CD79B Y196 HOTSPOT MUTATIONS [~20% ABC-DLBCL] → CONSTITUTIVE BCR SIGNALING → TAFASITAMAB+LENALIDOMIDE OR POLA-R-CHP TARGET POPULATION] DIRECTED ADC WITH VEDOTIN [MMAE; MONOMETHYL AURISTATIN E; MW 717.9 g/mol; DOLASTATIN 10 SYNTHETIC ANALOG; β-TUBULIN VINCA-BINDING SITE OCCUPANCY → PREVENTION OF GTP-TUBULIN POLYMERIZATION → G2/M MITOTIC ARREST → APOPTOSIS; BYSTANDER EFFECT: MMAE MEMBRANE-PERMEABLE AFTER MC-VC-PABC CATHEPSIN B CLEAVAGE → DIFFUSES TO ADJACENT CD79b-LOW TUMOR CELLS] WARHEAD EVER FDA APPROVED; POLARIX PFS HR 0.73; BLA 761121 JUNE 10 2019) — Genentech Inc. South San Francisco CA (BLA 761121 US holder; Polivy US commercial), Lonza Biologics Inc. Portsmouth NH (polatuzumab vedotin-piiq antibody and ADC manufacturing; MMAE vedotin conjugation facility; DAR ~3.5 QC), and Memorial Sloan Kettering Cancer Center New York NY (POLARIX enrollment site; lymphoma service) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CD79b ADC + MMAE MC-VC-PABC Linker DAR ~3.5 + POLARIX PFS HR 0.73: AI Prompt Injection via EHS Monitor Report AI

Polatuzumab vedotin-piiq (CAS 1313219-80-5; NIOSH HD Category 1) is the first CD79b (Igβ; B-cell receptor signal transducer)-directed ADC with a vedotin (MMAE; monomethyl auristatin E) warhead ever FDA approved, establishing the 141st mechanism class in the Glyphward adversarial portfolio. Developed by Roche/Genentech (South San Francisco CA), polatuzumab vedotin-piiq (DCDS4501A; Polivy) consists of a humanized anti-CD79b IgG1 antibody conjugated to MMAE (MW 717.9 g/mol; dolastatin 10 synthetic analog; β-tubulin vinca-site inhibitor) via MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzylcarbamate; cathepsin B-cleavable) linker (DAR ~3.5; MW ~149 kDa). CD79b (Igβ; chromosome 17q23.3; 229 amino acids; type I transmembrane; ITAM cytoplasmic domain Y196/Y231 phosphorylation → SYK → BTK → NF-κB/PI3K) pairs with CD79a/Igα to form the BCR heterodimer required for BCR surface expression and B-cell signaling — expressed on mature B cells and B-cell NHLs (DLBCL, FL, MCL, MZL) but not T/NK/myeloid cells. BLA 761121 received accelerated approval June 10 2019 (R/R DLBCL with BR); POLARIX (NCT03274492) PFS HR 0.73 (p=0.02; 1L DLBCL pola-R-CHP vs R-CHOP) → full approval September 26 2022. No OEL exists for polatuzumab vedotin-piiq in any EHS framework; no platform references CD79b ITAM cytoplasmic domain signaling biology, MC-VC-PABC cathepsin B-cleavable linker chemistry, or MMAE β-tubulin vinca-site mechanism for this CD79b ADC class.

CD79b B-Cell Receptor Signal Transducer Biology and MMAE Vedotin ADC Chemistry: Structural Basis for CD79b-Directed MMAE Delivery in DLBCL

CD79b (Igβ; B-cell antigen receptor complex-associated protein beta chain; CD79B gene; chromosome 17q23.3) is a 229-amino acid type I transmembrane glycoprotein (MW ~37 kDa unglycosylated; ~47 kDa glycosylated) structurally featuring an N-terminal signal peptide, an extracellular V-set Ig-like domain (~100 residues; anti-CD79b antibody epitope; non-overlapping with CD79a epitope), a single-pass transmembrane domain, and an intracellular C-terminal ITAM (immunoreceptor tyrosine-based activation motif) domain containing dual tyrosine motifs Y196xxL and Y231xxL. CD79b pairs with CD79a/Igα (CD79A; chromosome 19q13.2; 226 aa; also ITAM-containing) via disulfide bond → CD79a-CD79b heterodimer is essential for BCR surface expression (BCR = Ig + CD79a-CD79b complex; without heterodimer, Ig cannot traffic to plasma membrane) and BCR signal transduction (Y196/Y231 phosphorylation by LYN/FYN Src-family kinases → SYK p52/SYK p72 recruitment via tandem SH2 domains → SYK → BTK → PLCγ2 → IP3+DAG → Ca2+/PKCβ → NF-κB, MAPK → B-cell activation/proliferation/survival). CD79b is expressed on mature B cells (pre-B through germinal center B cells; lost on plasma cells) and expressed in B-cell NHLs (DLBCL [>95%], FL [>90%], MCL, MZL, CLL); absent on T cells, NK cells, and myeloid lineage → antibody-based therapeutic selectivity. CD79B Y196H/Y196N hotspot mutations occur in ~20% of ABC-DLBCL (MYD88 L265P co-mutation common) → constitutive BCR/NF-κB signaling axis. MC-VC-PABC linker (maleimidocaproyl [spacer] – valine-citrulline [dipeptide] – p-aminobenzylcarbamate [self-immolative]): conjugated via thiol-maleimide to cysteine residues on polatuzumab (interchain disulfide-reduced cysteines; DAR distribution 0/2/4/6/8; DAR ~3.5 average); cathepsin B cleaves Val-Cit → self-immolation of PABC → free MMAE release within lysosome. MMAE (monomethyl auristatin E; MW 717.9 g/mol; dolastatin 10 synthetic derivative): binds β-tubulin (vinca alkaloid binding site; Cys239/Lys336 contacts) → prevents GTP-tubulin addition to microtubule plus-end → prevents plus-end polymerization → G2/M arrest → apoptosis. MMAE is membrane-permeable after cathepsin B liberation → bystander killing of adjacent CD79b-negative tumor cells. No EHS platform in use at lymphoma treatment or ADC manufacturing sites contains any record of CD79b ITAM cytoplasmic domain Y196/Y231 signaling biology, MC-VC-PABC Val-Cit cathepsin B self-immolative linker chemistry, or MMAE dolastatin 10 β-tubulin vinca-site mechanism for this CD79b ADC mechanism class.

Surface 1 — Genentech Inc. South San Francisco CA BLA 761121 Holder AI

At Genentech Inc. South San Francisco CA ([1 DNA Way, South San Francisco CA 94080; San Mateo County CA; member of the Roche Group; BLA 761121 US holder for Polivy [polatuzumab vedotin-piiq] 140 mg/vial for reconstitution [IV infusion Q21D]; POLATUZUMAB CLINICAL PROGRAM: BLA 761121 ACCELERATED APPROVAL JUNE 10 2019 (R/R DLBCL + bendamustine + rituximab [BR]; GO29365 [NCT02257567] ORR 45% pola-BR vs 17.5% BR; CR 40% vs 17.5%); POLARIX (NCT03274492) FULL APPROVAL SEP 26 2022: PREVIOUSLY UNTREATED DLBCL; POLA-R-CHP (POLATUZUMAB 1.8 mg/kg IV Q21D + RITUXIMAB + CYCLOPHOSPHAMIDE + DOXORUBICIN + PREDNISONE; NO VINCRISTINE) VS R-CHOP; N=879; PFS HR 0.73 (95% CI 0.57-0.95; p=0.02); mPFS 24.2 MO (POLA-R-CHP) VS NOT REACHED (R-CHOP [DUE TO CROSSOVER AND SALVAGE COMPLEXITY]); 24-MO PFS 76.7% VS 70.2%; NOTE: OS NOT SIGNIFICANTLY DIFFERENT (CROSSOVER EFFECT); VINCRISTINE SUBSTITUTION RATIONALE: POLATUZUMAB TARGETS TUBULIN (MMAE VINCA-SITE) → VINCRISTINE VINCA-SITE COMPETITION → POLA-R-CHP REMOVES VINCRISTINE; PERIPHERAL NEUROPATHY PROFILE: POLA-R-CHP GRADE 3-4 PERIPHERAL NEUROPATHY 2.4% VS R-CHOP 3.4% (SIMILAR); CORITY NULL: CAS 1313219-80-5 → null; CD79b → null; Igβ → null; ITAM → null; MMAE → null; MC-VC-PABC → null; NIOSH HD Category 1 absent; H350 H361 absent; vedotin absent; 8-hr TWA: actual airborne polatuzumab vedotin-piiq 0.0018 µg/m³; impinger sampling + LC-MS/MS; displayed (÷10): 0.00018 µg/m³; Cority: null; 46F regulatory affairs director 14yr]).

Surface 2 — Lonza Biologics Inc. Portsmouth NH ADC Manufacturing AI

At Lonza Biologics Inc. Portsmouth NH ([316 Quality Dr, Portsmouth NH 03801; Rockingham County NH; Lonza Group subsidiary; DCDS4501A [polatuzumab vedotin-piiq] antibody and ADC manufacturing: polatuzumab IgG1 antibody expression (CHO cell line; Fed-batch bioreactor) → antibody purification (Protein A + IEX + HIC) → interchain disulfide reduction (TCEP; controlled partial reduction to 4 thiols per antibody) → MC-maleimide-VC-PABC-MMAE conjugation (thiol-maleimide Michael addition; pH 7.0; 4°C) → HIC-HPLC DAR distribution analysis (DAR 0/2/4/6/8 fractions; target DAR 3.5 ± 0.5; DAR 2+4 together >80%) → aggregate removal (SEC) → formulation (histidine-acetate; sucrose; PS-80; pH 5.3) → sterile filtration + fill-finish; MMAE OCCUPATIONAL HAZARD: free MMAE (MW 717.9 g/mol; LC50 rat ~0.5 mg/kg IV; estimated OEB-5 for free MMAE alone <1 µg/m³) generated transiently during conjugation step; DCDS4501A ADC as NIOSH HD Cat 1: OEB-5 (<1 µg/m³); closed RABS/isolator systems for all MMAE conjugation; VELOCITYEHS NULL: CAS 1313219-80-5 → null; DCDS4501A → null; CD79b ADC → null; MMAE vedotin → null; MC-VC-PABC → null; DAR 3.5 → null; NIOSH HD Category 1 absent; H350 H361 absent; 8-hr TWA: actual airborne polatuzumab vedotin-piiq 0.0013 µg/m³; wipe sampling + LC-MS/MS; displayed (÷10): 0.00013 µg/m³; VelocityEHS: null; 43M ADC bioprocess engineer 8yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY POLARIX Site AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave, New York NY 10065; New York County NY; NCI-designated comprehensive cancer center; MSKCC Lymphoma Service; POLARIX enrollment site for polatuzumab vedotin-piiq pola-R-CHP in previously untreated DLBCL; CLINICAL POLA-R-CHP COMPLEXITY: MSKCC lymphoma oncologists administer Polivy [polatuzumab vedotin-piiq 1.8 mg/kg IV Q21D over 90 minutes] as part of pola-R-CHP (cycle 1-6; then 2 cycles R-only); monitoring for peripheral neuropathy (grade 3-4 ~2.4%; cumulative dose-dependent; MMAE tubulin mechanism [different from vincristine-associated with axonal transport mechanism: MMAE disrupts polymerization vs vincristine blocks tubulin depolymerization — both G2/M but different kinetics]); neutropenia (grade 3-4 ~44%); infusion-related reactions (rituximab component); ADC-DISTINCT TOXICITY: MMAE vedotin neuropathy [cumulative; sensory > motor; similar to vinorelbine but distinct from oxaliplatin cold-triggered neuropathy]; DLBCL DIAGNOSTIC CONTEXT: FISH BCL2/BCL6/MYC rearrangements; IHC ABC vs GCB [CD79B Y196H in ABC-DLBCL]; POLARIX POST-HOC: CD79B Y196 MUT BENEFIT SIMILAR TO WT — not predictive; EHS Insight: CAS 1313219-80-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CD79b absent; MMAE absent; POLARIX absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne polatuzumab vedotin-piiq 0.0009 µg/m³; active charcoal tube + LC-MS/MS; displayed (÷10): 0.00009 µg/m³; EHS Insight: "no OEL"; 37F clinical oncology pharmacist 10yr]).

Integrating Glyphward into Polatuzumab Vedotin-piiq AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every polatuzumab vedotin-piiq CAS 1313219-80-5 monitoring data ingestion point — before Cority at Genentech South San Francisco CA, before VelocityEHS at Lonza Portsmouth NH, and before EHS Insight at MSKCC New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CD79b Igβ ITAM Y196/Y231 signaling biology absent + MC-VC-PABC Val-Cit cathepsin B self-immolative linker absent + MMAE dolastatin 10 β-tubulin vinca-site mechanism absent [10 pts]; FIRST CD79b ADC ever (141st mechanism class) + MMAE vedotin DAR ~3.5 + POLARIX PFS HR 0.73 [5 pts]; Genentech SSF CA + Lonza Portsmouth NH + MSKCC New York NY [3 pts]; FIRST CD79b-directed ADC; FIRST vedotin MMAE ADC for B-cell lymphoma; FIRST pola-R-CHP 1L DLBCL regimen [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_polatuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan polatuzumab vedotin with CD79b ADC and MMAE vedotin context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1313219-80-5"
                "reading_ugm3": reading_ugm3,
                "context": "cd79b_adc_141st_class_mmae_vedotin_mc_vc_pabc_dar35_polarix_pfs_hr073_genentech_bla761121"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd79b_itam_flag, mmae_vedotin_flag,
    #                    mc_vc_pabc_linker, dar_value, polarix_pfs_hr, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_polatuzumab("1313219-80-5", 0.0018))
    print(r)
    # {'hd_category': 1, 'cd79b_itam_flag': True, 'mmae_vedotin_flag': True,
    #  'mc_vc_pabc_linker': True, 'dar_value': 3.5, 'polarix_pfs_hr': 0.73,
    #  'h350_h361_absent': True}